Q1 EPS Estimate for Corcept Therapeutics Lowered by Analyst

Corcept Therapeutics Incorporated (NASDAQ:CORT) – Zacks Research cut their Q1 2025 EPS estimates for shares of Corcept Therapeutics in a research report issued on Wednesday, December 18th. Zacks Research analyst K. Das now forecasts that the biotechnology company will post earnings of $0.27 per share for the quarter, down from their previous estimate of $0.29. The consensus estimate for Corcept Therapeutics’ current full-year earnings is $1.35 per share. Zacks Research also issued estimates for Corcept Therapeutics’ Q2 2025 earnings at $0.34 EPS, Q3 2025 earnings at $0.42 EPS, Q4 2025 earnings at $0.53 EPS, Q2 2026 earnings at $0.55 EPS, Q3 2026 earnings at $0.71 EPS and FY2026 earnings at $2.41 EPS.

Corcept Therapeutics (NASDAQ:CORT) last announced its earnings results on Wednesday, October 30th. The biotechnology company reported $0.41 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.27 by $0.14. The firm had revenue of $182.55 million during the quarter, compared to analysts’ expectations of $171.97 million. Corcept Therapeutics had a return on equity of 24.54% and a net margin of 22.35%. The business’s revenue was up 47.7% on a year-over-year basis. During the same period in the prior year, the firm earned $0.28 EPS.

Other analysts have also recently issued reports about the company. Sandler O’Neill reaffirmed a “buy” rating on shares of Corcept Therapeutics in a research report on Friday, October 18th. HC Wainwright reiterated a “buy” rating and issued a $80.00 price objective on shares of Corcept Therapeutics in a research report on Thursday, October 31st. Piper Sandler upped their price objective on shares of Corcept Therapeutics from $38.00 to $67.00 and gave the stock an “overweight” rating in a research report on Wednesday, September 18th. StockNews.com downgraded shares of Corcept Therapeutics from a “strong-buy” rating to a “buy” rating in a report on Monday, November 25th. Finally, Truist Financial increased their price target on shares of Corcept Therapeutics from $65.00 to $76.00 and gave the stock a “buy” rating in a report on Monday, September 30th. Six equities research analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, the company currently has a consensus rating of “Buy” and an average price target of $65.25.

Corcept Therapeutics Price Performance

Shares of CORT opened at $51.40 on Friday. The company has a market capitalization of $5.39 billion, a price-to-earnings ratio of 40.79 and a beta of 0.51. Corcept Therapeutics has a fifty-two week low of $20.84 and a fifty-two week high of $62.22. The firm has a 50-day simple moving average of $53.83 and a 200-day simple moving average of $41.98. The company has a debt-to-equity ratio of 0.01, a quick ratio of 3.64 and a current ratio of 3.70.

Institutional Trading of Corcept Therapeutics

Hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. SG Americas Securities LLC grew its holdings in shares of Corcept Therapeutics by 19.8% during the second quarter. SG Americas Securities LLC now owns 8,184 shares of the biotechnology company’s stock worth $266,000 after buying an additional 1,353 shares in the last quarter. Nisa Investment Advisors LLC grew its stake in Corcept Therapeutics by 10.5% in the 2nd quarter. Nisa Investment Advisors LLC now owns 5,368 shares of the biotechnology company’s stock worth $174,000 after acquiring an additional 510 shares during the period. Louisiana State Employees Retirement System raised its holdings in Corcept Therapeutics by 2.7% in the 2nd quarter. Louisiana State Employees Retirement System now owns 46,100 shares of the biotechnology company’s stock valued at $1,498,000 after acquiring an additional 1,200 shares during the last quarter. Calamos Advisors LLC purchased a new position in shares of Corcept Therapeutics during the 2nd quarter worth $373,000. Finally, Allspring Global Investments Holdings LLC lifted its stake in shares of Corcept Therapeutics by 0.4% during the 2nd quarter. Allspring Global Investments Holdings LLC now owns 127,348 shares of the biotechnology company’s stock worth $4,138,000 after purchasing an additional 541 shares during the period. Hedge funds and other institutional investors own 93.61% of the company’s stock.

Insider Activity at Corcept Therapeutics

In related news, insider Gary Charles Robb sold 11,000 shares of the company’s stock in a transaction that occurred on Tuesday, October 1st. The stock was sold at an average price of $46.28, for a total value of $509,080.00. Following the sale, the insider now owns 22,772 shares of the company’s stock, valued at approximately $1,053,888.16. This represents a 32.57 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, insider Joseph Douglas Lyon sold 1,411 shares of the firm’s stock in a transaction on Friday, November 22nd. The stock was sold at an average price of $56.72, for a total value of $80,031.92. Following the transaction, the insider now directly owns 8,494 shares of the company’s stock, valued at $481,779.68. The trade was a 14.25 % decrease in their position. The disclosure for this sale can be found here. Insiders sold 26,811 shares of company stock worth $1,341,360 over the last 90 days. Company insiders own 20.50% of the company’s stock.

Corcept Therapeutics Company Profile

Corcept Therapeutics Incorporated engages in discovery and development of drugs for the treatment of severe endocrinologic, oncologic, metabolic, and neurologic disorders in the United States. It offers Korlym tablets medication for the treatment of hyperglycemia secondary to hypercortisolism in adult patients with endogenous cushing's syndrome; and who have type 2 diabetes mellitus or glucose intolerance and have failed surgery or are not candidates for surgery.